Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Pancreas Cancer
Type
Interventional
Phase
Not Applicable
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Supportive Care

Participation Requirements

Age
Between 18 years and 85 years
Gender
Both males and females

Description

Pancreatic cancer is a rapidly developing cancer with a poor prognosis. 5-year survival is 6% in Europe and the USA. The FOLFIRINOX protocol has become the standard medical treatment for this pathology. However, FOLFIRINOX is the cause of severe toxicities dominated by leuko-neutropenia, thrombocyto...

Pancreatic cancer is a rapidly developing cancer with a poor prognosis. 5-year survival is 6% in Europe and the USA. The FOLFIRINOX protocol has become the standard medical treatment for this pathology. However, FOLFIRINOX is the cause of severe toxicities dominated by leuko-neutropenia, thrombocytopenia, diarrhea, nausea-vomiting, anorexia, asthenia, weight loss and peripheral sensory neuropathy. Therefore, its indication is limited to patients in good general condition with a Performance Status of 0 or 1 (WHO classification). In practice, it is interrupted upon the occurrence of grade 3-4 toxicities, hematological and / or clinical, which very often causes deterioration in the performance status and quality of life of patients. To date, there is no prospective study assessing the qualitative and quantitative impact of FOLFIRINOX in real time on the daily life of patients with pancreatic cancer. Such monitoring would allow early identification of the deterioration or improvement in the health of these fragile patients while they are not hospitalized, and trigger proactive interventions when necessary, in order to avoid rapid deterioration of the patient leading to hospitalization and often to the interruption of a generally effective treatment. It is in this context that the study presented here proposes to monitor the rhythms, symptoms and body weight of patients with advanced pancreatic cancer during the month following the 1st cycle of FOLFIRINOX in conventional administration using the platform. PiCADo mobile.

Tracking Information

NCT #
NCT04263948
Collaborators
Not Provided
Investigators
Not Provided